251 related articles for article (PubMed ID: 16086715)
1. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Löfberg R; Feagan BG; Hanauer SB; Campieri M; Greenberg GR
Am J Gastroenterol; 2005 Aug; 100(8):1780-7. PubMed ID: 16086715
[TBL] [Abstract][Full Text] [Related]
2. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial.
Hanauer S; Sandborn WJ; Persson A; Persson T
Aliment Pharmacol Ther; 2005 Feb; 21(4):363-71. PubMed ID: 15709986
[TBL] [Abstract][Full Text] [Related]
3. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
[TBL] [Abstract][Full Text] [Related]
4. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission.
de Jong DJ; Bac DJ; Tan G; de Boer SY; Grabowsky IL; Jansen JB; Greinwald R; Naber TH
Neth J Med; 2007 Oct; 65(9):339-45. PubMed ID: 17954953
[TBL] [Abstract][Full Text] [Related]
5. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis.
Lichtenstein GR; Bengtsson B; Hapten-White L; Rutgeerts P
Aliment Pharmacol Ther; 2009 Mar; 29(6):643-53. PubMed ID: 19035972
[TBL] [Abstract][Full Text] [Related]
6. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
[TBL] [Abstract][Full Text] [Related]
7. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
Tromm A; Bunganič I; Tomsová E; Tulassay Z; Lukáš M; Kykal J; Bátovský M; Fixa B; Gabalec L; Safadi R; Kramm HJ; Altorjay I; Löhr H; Koutroubakis I; Bar-Meir S; Stimac D; Schäffeler E; Glasmacher C; Dilger K; Mohrbacher R; Greinwald R;
Gastroenterology; 2011 Feb; 140(2):425-434.e1; quiz e13-4. PubMed ID: 21070781
[TBL] [Abstract][Full Text] [Related]
8. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
[TBL] [Abstract][Full Text] [Related]
9. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.
Gross V; Andus T; Caesar I; Bischoff SC; Lochs H; Tromm A; Schulz HJ; Bär U; Weber A; Gierend M; Ewe K; Schölmerich J
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):905-9. PubMed ID: 8889459
[TBL] [Abstract][Full Text] [Related]
10. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
N Engl J Med; 1994 Sep; 331(13):836-41. PubMed ID: 8078529
[TBL] [Abstract][Full Text] [Related]
11. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
[TBL] [Abstract][Full Text] [Related]
12. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.
Thia KT; Sandborn WJ; Lewis JD; Loftus EV; Feagan BG; Steinhart AH; Hanauer SB; Persson T; Sands BE
Am J Gastroenterol; 2008 Dec; 103(12):3123-31. PubMed ID: 18786111
[TBL] [Abstract][Full Text] [Related]
13. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study.
Tursi A; Giorgetti GM; Brandimarte G; Elisei W; Aiello F
Med Sci Monit; 2006 Jun; 12(6):PI29-32. PubMed ID: 16733496
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.
Reinisch W; Panés J; Lémann M; Schreiber S; Feagan B; Schmidt S; Sturniolo GC; Mikhailova T; Alexeeva O; Sanna L; Haas T; Korom S; Mayer H
Am J Gastroenterol; 2008 Sep; 103(9):2284-92. PubMed ID: 18671816
[TBL] [Abstract][Full Text] [Related]
15. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial.
Miehlke S; Madisch A; Bethke B; Morgner A; Kuhlisch E; Henker C; Vogel G; Andersen M; Meier E; Baretton G; Stolte M
Gastroenterology; 2008 Nov; 135(5):1510-6. PubMed ID: 18926826
[TBL] [Abstract][Full Text] [Related]
16. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
[TBL] [Abstract][Full Text] [Related]
17. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
[TBL] [Abstract][Full Text] [Related]
18. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Feagan BG; Sandborn WJ
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
[TBL] [Abstract][Full Text] [Related]
19. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study.
Suzuki Y; Motoya S; Takazoe M; Kosaka T; Date M; Nii M; Hibi T
J Crohns Colitis; 2013 Apr; 7(3):239-47. PubMed ID: 22766525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
